GLUE
Monte Rosa·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 2
Ample Liquidity
High Gross Profit Margin
EPS Below Expectations
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About GLUE
Monte Rosa Therapeutics, Inc.
A biotech company that develops novel molecular glue degrader (MGD)-based medicines
321 Harrison Avenue, Suite 900, Boston, Massachusetts, 02118
--
Monte Rosa Therapeutics, Inc., was incorporated in Delaware in November 2019. The company is a biopharmaceutical company that develops a range of new small molecule precision medicines that use the body's natural mechanisms to selectively degrade treatment-related proteins. The company has developed a proprietary protein degradation platform called QuEEN, which is capable of rapidly identifying protein targets and molecular gel degraders (MGDs), product candidates designed to eliminate therapeutically relevant proteins in a highly selective manner. The company believes that the small molecule MGD may have significant advantages over existing treatments because the company allows the targeting of proteins that are considered undruggable or undermedicated. The company focuses on therapeutic goals backed by strong biological and genetic principles, with the goal of discovering and developing new precision medicines. These opportunities include oncology and non-oncology indications, including immunology, inflammation, neurological and genetic diseases.
Company Financials
EPS
GLUE has released its 2025 Q3 earnings. EPS was reported at -0.33, versus the expected -0.35, beating expectations. The chart below visualizes how GLUE has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
GLUE has released its 2025 Q3 earnings report, with revenue of 12.77M, reflecting a YoY change of 38.54%, and net profit of -27.08M, showing a YoY change of -13.50%. The Sankey diagram below clearly presents GLUE's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
